Physician profile
Gary Goldman
NPI 1366792962
$4,710.45
in general payments reported to CMS, 2019-2025
36 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $357 · 2021: $195 · 2022: $612 · 2023: $1,594 · 2024: $294 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.79 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.86 | 2019-2025 | Tagrisso, Andexxa, Farxiga |
| Janssen Biotech, INC. | $750.73 | 2021-2025 | Carvykti, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $325.33 | 2020-2024 | Onureg, Opdivo |
| Scpharmaceuticals INC. | $250.49 | 2023 | |
| Stemline Therapeutics INC. | $190.53 | 2023 | Orserdu |
| Genentech USA, INC. | $188.87 | 2019-2025 | Itovebi, Phesgo |
| Amgen INC. | $182.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $154.04 | 2023-2024 | Arexvy, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $151.96 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $135.00 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $128.84 | 2022-2024 | Ninlaro |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Merck Sharp & Dohme LLC | $121.95 | 2019 | |
| Insmed, INC. | $120.97 | 2019 | |
| Seagen INC. | $100.87 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $100.87 | 2023-2025 | Xtandi |
| Hologic Sales and Service, LLC | $86.24 | 2022-2023 | Thinprep 2000 Processor |
| Irhythm Technologies, INC. | $83.34 | 2020 | |
| Sumitomo Pharma America, INC. | $74.27 | 2023-2025 | Orgovyx |
| Myovant Sciences INC. | $74.23 | 2021-2022 | |
| Eisai INC. | $72.93 | 2023-2025 | |
| Pfizer INC. | $61.84 | 2021-2023 | |
| Celgene Corporation | $58.46 | 2022-2023 | Opdualag |
| Gilead Sciences, INC. | $49.54 | 2023-2024 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $42.38 | 2019 | |
| Lilly USA, LLC | $38.01 | 2019-2020 | |
| Caris Mpi, INC. | $36.06 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $25.00 | 2023 | Sylvant |
| Exelixis INC. | $23.82 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $23.03 | 2024 | Enhertu |
| Array Biopharma INC | $20.94 | 2024 | Mektovi, Xalkori, Braftovi |
| Global Blood Therapeutics, INC. | $20.22 | 2022 | |
| Therapeuticsmd, INC. | $18.17 | 2020 | |
| Genzyme Corporation | $18.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.84 | 2022 | |
| Eusa Pharma (US) LLC | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.